$1.66
-0.07 (-4.05%)
Open$1.72
Previous Close$1.73
Day High$1.72
Day Low$1.56
52W High$6.48
52W Low$0.59
Volume—
Avg Volume820.8K
Market Cap36.52M
P/E Ratio—
EPS$-6.56
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+592.8% upside
Current
$1.66
$1.66
Target
$11.50
$11.50
$7.99
$11.50 avg
$12.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 28.53M | 987.4K | 951.3K |
| Net Income | -2,909,466,935 | -74,062 | -66,038 |
| Profit Margin | -374.3% | -7.5% | -6.9% |
| EBITDA | -2,819,713,141 | -123,235 | -109,691 |
| Free Cash Flow | — | -44,936 | -40,091 |
| Rev Growth | — | +23.6% | +13.9% |
| Debt/Equity | 0.01 | 1.06 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |